- Lonza has launched TheraPEAK® AmpliCell® Cytokines and TheraPEAK® 293-GT® Medium to expand GMP solutions for cell and gene therapy.
- The new products are designed to improve immune cell expansion, activation, and AAV production in research and GMP workflows.
Lonza has introduced two new TheraPEAK® products aimed at advancing cell and gene therapy manufacturing. The additions, AmpliCell® Cytokines and 293-GT® Medium, provide regulatory-ready, scalable solutions for both research and GMP environments.
TheraPEAK® AmpliCell® Cytokines are produced in a mammalian expression system and engineered for high biological activity. They support the expansion, activation, and differentiation of immune cells with proper folding and glycosylation, providing native-like structure and function that bacterial systems cannot replicate. The solution ensures batch-to-batch consistency and predictability for sensitive applications.
The TheraPEAK® 293-GT® Medium is a chemically defined, animal–origin–free system optimised for adeno-associated virus (AAV) production in suspension HEK293 cells. The medium integrates with existing workflows, supports commercially available transfection reagents, and enables strong AAV titers with high full-to-empty capsid ratios. It offers a scalable, drop-in-ready option for gene therapy programs.
TheraPEAK® products have been used in FDA-approved therapies and more than 130 clinical trials worldwide. According to Lonza, the new offerings provide high-performance, scalable, and GMP-compatible tools that streamline cell and gene therapy workflows from discovery through clinical development.
“The introduction of AmpliCell® Cytokines and the 293-GT® Medium to our TheraPEAK® Range greatly enhances our offering for cell and gene therapy customers, providing them with reliable solutions to support their drug development efforts.”
Mike Goetter, Head of Bioscience, Specialized Modalities at Lonza
